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and growth by acting through the PI3K/PTEN/AKT and RAS-
MAPK pathways [1]. HER2 overexpression and gene amplification 
are assessed by immunohistochemistry (IHC) and fluorescence 
in situ hybridization (FISH) respectively, on biopsies or surgical 
specimens, and have been described in a number of human tumors 
including breast, gastric, and endometrial cancers [2]. Therefore, it is 
an appealing target in the treatment of these malignancies.
HER2 overexpression/gene amplification is observed in up to 30% 
of breast cancers [3]. Positivity is associated with aggressive disease and 
a worse prognosis when compared to HER2 negative breast cancer. 
Trastuzumab is a monoclonal antibody that targets HER2, and has 
been shown to prolong overall survival and progression free survival 
in early and metastatic breast cancer in a number of clinical trials [1,3].
The role of HER2 in gastric and gastro-esophageal junction 
adenocarcinoma is less well defined, with reported overexpression 
rates varying between 8 to 50 % of cases [2]. Equally, data on its 
prognostic value is not consistent. The ToGA trial, a phase III 
randomized clinical trial reported in 2010, investigated the role of 
Trastuzumab in patients with HER2 positive metastatic gastric and 
gastro-esophageal junction adenocarcinoma [4]. The addition of 
Trastuzumab led to an increase in the median overall survival by 2.7 
months compared to standard chemotherapy alone.
Our understanding of the biological role of HER2 overexpression/
gene amplification in gastric cancer and the therapeutic implications 
is still evolving. We report the results of screening for HER2 
overexpression/gene amplification in patients with advanced gastric 
and gastro-esophageal cancers in a tertiary institute; we further 
discuss their treatment and survival.
Methods
The study was conducted at St James’s University Hospital, a 
tertiary referral center for esophageal and gastric cancer. Patients 
included in the study had metastatic or inoperable gastric or gastro-
esophageal junction adenocarcinoma and treated in the period 
between April 2010 and April 2013.
Abstract
Background: Trastuzumab has been approved for patients 
with human epidermal growth factor receptor 2 (HER2) over 
expression and gene amplification metastatic gastric cancer. Here 
we present the prevalence of HER2 positive gastric cancer in an 
Irish population, the use of Trastuzumab in first line and beyond 
progression.
Methods: The study was conducted in St James’s Hospital, Dublin. 
A retrospective analysis of the date of patients with HER2 positive 
gastric cancer over a period of 3 years was carried out. Her2 
positive was defined as immunohistochemistry (IHC) score of +3, of 
IHC score of +2 and increased gene copy number by fluorescence 
in situ hybridization (FISH). Overall survival was calculated from the 
day of initiation of treatment with Trastuzumab until death.
Results: During the study period 140 patients with gastric and 
gastro-esophageal junction adenocarcinoma were treated. Out 
of those, 30 (21.4%) had HER2 positive disease. Among HER2 
positive disease patients 18 (12.8%) were treated with first line 
Trastuzumab containing regimen with a median overall survival 
of 13 months. Nine (50%) developed progressive disease while 
on Trastuzumab and of those, 4 (22.2%) patients continued on 
Trastuzumab beyond progression, two (11.1%) of whom achieved 
stable disease and a prolonged survival.
Conclusion: HER2 positivity rate in an Irish population with 
advanced gastric and gastro-esophageal junction adenocarcinoma 
is 21.4%. Treatment with Trastuzumab in the first line in combination 
with chemotherapy is a reasonable approach. Continuation of 
Trastuzumab beyond progression is a feasible strategy that 
requires further exploration.
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Introduction
Human epidermal growth factor receptor-2 (HER2) is a 
member of the epidermal growth factor receptor family1. HER2 is a 
transmembrane tyrosine kinase receptor coded by the ERBB gene on 
chromosome 17. It plays an important role in regulating cell survival 
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Retrospective review of prospectively collected patients’ data was 
carried out, data including patients’ demographics, disease staging, 
histological subtype, treatment and survival were gathered from 
patients’ electronic and written records.
HER2 positivity was defined as IHC +3 or IHC +2 and FISH 
positive [2,4,5]. HER2 negativity was defined as IHC 0/1 (1+), or 
IHC +2 and FISH negative. Median overall survival was calculated 
for patients treated with Trastuzumab from the day of treatment 
initiation with Trastuzumab until death. Data was censored on the 
first of May 2013. Data on compliance with treatment, treatment 
toxicity, and treatment interruptions were available for all patients 
treated in our center. While on Trastuzumab, Patients’ cardiac 
function was monitored by echocardiogram or Multi Gated 
Acquisition Scan (MUGA) every three months. Treatment toxicity 
was graded according to the National Cancer Institute common 
toxicity criteria version 4.0. Statistical analysis was carried out using 
GraphPad Prism 6®.
Results
During the study period, 162 patients presented with metastatic or 
inoperable gastric and gastro-esophageal junction adenocarcinoma, 
of these 140 (86.4%) were assessed for HER2 protein overexpression/
gene amplification. Sixty one (43.6%) had gastric adenocarcinoma 
and 79 (56.4%) had gastro-esophageal junction adenocarcinoma. 
All patients’ samples were assessed using immunohistochemistry 
(HerceptTest, Dako, Denmark or PATHWAY anti-HER-2 (4B5), 
Ventana, Tucson, AZ. USA). Only samples with IHC score of +2 
were assessed subsequently with FISH, results of which are shown 
in Table 1.
Thirty (21.4%) patients were found to have HER2 positive gastric 
or gastro-esophageal adenocarcinoma; their characteristics are 
outlined in Table 2. Of these, 18 were treated with a Trastuzumab 
containing regimen. 12 patients did not receive Trastuzumab as part 
of their treatment. The reasons for this were: 6 elected to be treated 
in another institute, 5 were deemed unfit for systemic therapy, and 1 
patient declined treatment. Among the 18 patients who did receive 
Trastuzumab, the drug was given in combination with Oxaliplatin and 
a fluoropyrimidine (either Capecitabine or Fluorouracil) in 9. HER2 
status was unavailable at the time of treatment initiation in 6 patients, 
whose initial treatment therefore consisted of Epiduracin, Oxaliplatin 
and a fluoropyrimidine (either Capecitabine or Fluorouracil). 
Following one or two cycles, when HER2 status was subsequently 
reported, Epiduracin was replaced with Trastuzumab. The remaining 
3 received Trastuzumab in combination with flurouracil.
In the cohort treated with Trastuzumab, 9 patients developed 
progressive disease while on treatment, and 5 of them were deemed 
unfit and died without receiving additional therapy. 4 continued 
on Trastuzumab beyond progression and among these, the 
accompanying regimen was switched from an initial combination of 
Oxaliplatin and a fluoropyrimidine to Docetaxel in three, and one 
received radiotherapy in combination.
The median overall survival for patients treated with a 
Trastuzumab containing regimen was 13 months (range 1-36 
Table1: Results of HER2 assessment.
IHC score N =140
0 30 (21%)
+1 64 (46%)
+2 25 (18%)
+3 21 (15%)
FISH No= 25
HER2 amplified 9 (36%)
HER2 Not amplified 16 (64%)
Table 2: HER2 positive patient characteristics.
Median age (years) 64 (32-76)
Sex
Male 21
Female 9
Ethnic Origin
Caucasian 29
Black 1
Tumour Location
Stomach 13 (43.4%)
Gastro-oesophageal junction 17 (56.6%)
Previous gastrectomy 8 (26.6%)
Previous chemotherapy 7 (23.3%)
Previous Radiotherapy 3 (10%)
Specimen Type
Surgical Specimen 8
Biopsy Specimen 22
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Figure 1:  Median overall survival of HER2 positive patients treated with Trastuzumab.
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months) (Figure 1). The mean number of Trastuzumab cycles given 
was 11.5 (range 1-49). No grade 3 or 4 cardiac toxicities occurred in 
patients treated with Trastuzumab.
Discussion
Gastric cancer is the second most common cause of cancer related 
deaths worldwide [6]. Combination chemotherapy remains an integral 
part of the treatment of both locally advanced and metastatic gastric 
cancer with modest improvement in survival rates when compared to 
other common malignancies such as breast and colorectal cancer [7]. 
Therefore, there is still a pressing need to develop novel therapeutic 
agents. Targeting HER2 in a selected cohort of patients promises to 
be an effective strategy.
Of our study population, 21.4% were HER2 positive, comparable 
to 22.1% reported in patients screened for eligibility in the ToGA trial 
[4]. It is important to note that both our cohort and that of the ToGA 
trial included patients with metastatic disease. Recent publications 
where only patients with early or locally advanced gastric and gastro-
esophageal junction carcinoma were included, showed rates of (Her-
2 Positivity of) 10.4% in the MAGIC trail cohort and 10.9% in the 
INT-0116 trial [8,9]. A potential source of bias in our study is that 
data was collected from a single institute. However, our center is the 
largest gastric cancer center in Ireland; we have screened 86.4% of 
all patients with metastatic gastric cancer. Therefore, it is likely that 
the rate of 21.4% that we found in this study cohort is a reflection of 
HER2 positivity rate in Irish patients with this disease.
In accordance with European medicines agency (EMEA) 
definition for Trastuzumab approval, we defined HER2 positive 
disease as IHC +3 or IHC+2 and FISH positive in both biopsies and 
surgical specimens. This definition varies from that of the FDA, which 
further differentiates between biopsies and surgical specimens. The 
FDA defines a HER2 positive biopsy as one that is IHC+3, or IHC+2 
and FISH positive. A HER2 positive surgical specimen, however, is 
one that is either IHC+3, or FISH positive regardless of IHC score 
[8]. Most studies reported a concordance rate between IHC and FISH 
of 90-98% [8-11].
The authors of the ToGA trial, the only large phase III trial thus far 
to report on HER2 positive gastric cancer, took a more liberal stance 
with regard to entry criteria, with 20% of their patients being FISH 
positive with IHC scores of 0 and 1 [4]. As previously mentioned, 
the ToGA trial reported a survival benefit of 2.7 months with a 
regimen combining cisplatin, a fluoropyrimidine and Trastuzumab 
compared to a regimen of cisplatin and a fluoropyrimidine alone. 
However, a preplanned analysis of patients with the above definition 
of HER2 positive disease (IHC+3 or IHC+2 and FISH positive) 
showed a survival benefit of 4.2 months. The results of the ToGA trial 
are the basis of Trastuzumab approval in HER positive gastric and 
gastro-esophageal adenocarcinoma. Our practice has consistently 
been to treat patients with HER2 positive inoperable or metastatic 
gastric and gastro-esophageal adenocarcinoma with a combination 
of Trastuzumab, oxaliplatin, and a fluoropyrimidne. In some cases, 
where the HER2 status is yet to be reported, we initiate treatment 
with oxaliplatin, a fluoropyrimidine, and epiduracin. We replace 
the latter with Trastuzumab in cases of HER2 positivity. Although 
epiduracin has been combined safely with Trastuzumab in advanced 
breast cancer, there is no data to support such combination in gastric 
cancer [7,11].
A unique feature of our study was the continuation of 
Trastuzumab beyond progression. Trastuzumab was continued with 
second line therapy in four patients. Two of them achieved stable 
disease with prolonged survival of 3 years in one patient and 1.1 
years in the other. The best evidence for the benefit of continuing 
Trastuzumab beyond progression comes from studies done on breast 
cancer, where clinical data show significant benefit in both Phase III 
studies and retrospective series [12-15]. To date there are no studies 
that have evaluated this approach in gastric cancer, however, a 
number of prospective clinical trials are currently underway to clarify 
this matter [2].
Several publications examined the prognostic and predictive role 
of HER2 overexpression/gene amplification in gastric cancer and 
have reported inconsistent results [2,7,16,17]. Recently, Prins et al. 
reported that HER2 positivity predicted poor survival in a cohort 
of 144 patients with locally advanced esophageal adenocarcinoma 
[11]. However, the authors used tissue microarrays (TMA) obtained 
from surgical specimens in their assessment of HER2 status. TMA 
generation carries a risk of sampling error with reported false negative 
rates of up to 24% [18]. In contrast, retrospective review of the MAGIC 
trial cohort showed that HER2 positivity did not predict the survival 
of 415 patients with locally advanced gastric or gastro-esophageal 
adenocarcinoma [8]. In addition, the researchers concluded that 
HER2 positivity did not predict response to epiduracin as was the 
case in breast cancer [8].
Several questions related to HER2 in gastric and gastro-esophageal 
cancer remain unanswered. What is the optimal definition of HER2 
positive disease in biopsies and surgical specimens? Does HER2 status 
change following chemotherapy? What is the role of Trastuzumab 
in the adjuvant setting and in the metastatic setting when there is 
progression while on treatment? These questions are currently being 
addressed in a number of phase III clinical trials [2,8,11].
Novel HER2 targeting agents include Lapatinib, an oral tyrosine 
kinase inhibitor that blocks HER2 downstream signaling [19]. The 
efficacy of Lapatinib in HER2 positive gastro-esophageal cancer is 
currently being tested in a phase III clinical trial [20]. Also, Pertuzumab, 
a monoclonal antibody that prevents HER2 dimerization, is in the 
final stages of clinical studies, where it is combined with Trastuzumab 
and standard chemotherapy [21].
Other targeted therapies include monoclonal antibodies that 
target the epidermal growth factor receptor (EGFR), namely 
Cetuximab and Panitumumab, which were investigated in gastric and 
esophageal cancer with disappointing results [22,23]. Bevacizumab, 
an anti-vascular endothelial growth factor receptor (VEGF) 
monoclonal antibody, increased progression free survival when 
added to standard chemotherapy in metastatic gastric cancer, as 
shown in the AVAGAST trial [24]. However, the AVAGAST study 
did not meet its primary endpoint which was overall survival. The 
role of Bevacizumab in early and localized gastro-esophageal cancer 
is being examined in an ongoing phase III clinical trial [25].
In summary, we have shown that the HER2 positivity rate in an 
Irish population with advanced gastric and gastro-esophageal junction 
adenocarcinoma is 21.4%. Treatment with Trastuzumab achieved a 
median survival of 13 months. Continuation of Trastuzumab beyond 
progression is a feasible strategy that requires further exploration.
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